Evaxion Biotech A/S (NASDAQ:EVAX) vs. Novozymes A/S (OTCMKTS:NVZMY) Head-To-Head Review

Novozymes A/S (OTCMKTS:NVZMY) and Evaxion Biotech A/S (NASDAQ:EVAX) are both basic materials companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.

Profitability

This table compares Novozymes A/S and Evaxion Biotech A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Novozymes A/S	N/A	N/A	N/A
Evaxion Biotech A/S	-347.83%	N/A	-79.40%

Analyst Ratings

This is a summary of current recommendations and price targets for Novozymes A/S and Evaxion Biotech A/S, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novozymes A/S	1	0	0	2	3.00
Evaxion Biotech A/S	0	0	2	0	3.00

Evaxion Biotech A/S has a consensus target price of $55.00, suggesting a potential upside of 1,536.90%. Given Evaxion Biotech A/S’s higher probable upside, analysts plainly believe Evaxion Biotech A/S is more favorable than Novozymes A/S.

Insider & Institutional Ownership

0.0% of Novozymes A/S shares are owned by institutional investors. Comparatively, 11.0% of Evaxion Biotech A/S shares are owned by institutional investors. 41.6% of Evaxion Biotech A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Novozymes A/S has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Evaxion Biotech A/S has a beta of -0.23, suggesting that its share price is 123% less volatile than the S&P 500.

Earnings & Valuation

This table compares Novozymes A/S and Evaxion Biotech A/S”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novozymes A/S	$2.60 billion	10.05	$439.08 million	$1.58	35.27
Evaxion Biotech A/S	$70,000.00	281.76	-$22.12 million	($0.29)	-11.59

Novozymes A/S has higher revenue and earnings than Evaxion Biotech A/S. Evaxion Biotech A/S is trading at a lower price-to-earnings ratio than Novozymes A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Novozymes A/S beats Evaxion Biotech A/S on 8 of the 13 factors compared between the two stocks.

About Novozymes A/S

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services. In addition, the company provides dishwashing, softener, microbial and medical cleaning services. Further, it provides corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; warm water species, recirculating aquaculture system; animal health and nutrition solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions. Additionally, the company provides carbon capture, leather and textiles solutions; enzyme solutions, including corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; warm water species and recirculating aquaculture system solutions; human health solutions, comprising brain, oral, protective and immune, and gastrointestinal health solutions; ethanol, biodiesel, renewable diesel, education, wastewater, and sewage sludge, and renewable diesel solutions; agriculture and industry, biogas food waste, food waste, biocatalysis, cell culture, diagnostics, enzyme, and biogas solutions. Furthermore, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S was founded in 1925 and is based in Bagsvaerd, Denmark.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.